Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore measured raltegravir concentrations in plasma in pre- and postdialyzer blood samples from 2 ESRD HIV-infected patients. The hemodialysis extraction ratio and raltegravir hemodialysis clearance were 5.5% and 9.1 ml/min in patient 1 and 9.5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis.
Moltó
José
J
Lluita contra la Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. jmolto@flsida.org
Sanz-Moreno
José
J
Valle
Marta
M
Cedeño
Samandhy
S
Bonal
Jordi
J
Bouarich
Hanane
H
Clotet
Bonaventura
B
D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000097:blood* / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000097:blood* / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D006435:Renal Dialysis / Q000379:methods*
D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium